The treatment of malignant solid tumors still faces challenges including the high risk of surgical resection and the severe side effects of chemotherapy. Moreover, existing clinical strategies often fail to meet the treatment needs of patients with inoperable tumors. In this study, a safe and efficient nanofiber patch was designed via electrospinning for combined photothermal-chemotherapy of abdominal tumors. By loading copper sulfide nanoparticles and polydopamine, the patch achieved efficient photothermal effects under safe NIR II laser irradiation. Moreover, the patch exhibited pH/NIR dual-responsive drug release through polydopamine protonation and photothermally enhanced diffusion. With these superior properties, the implantable patch can non-invasively ablate solid tumors via photothermal therapy and eliminate residual cancer cells through controllable chemotherapy, while maintaining low systemic toxicity. Notably, this safe and effective therapeutic strategy exhibited significantly higher tumor apoptosis (68.6%) than the control of only chemotherapy patch (29.3%) or photothermal therapy patch (42.5%). The DPPCP patch + NIR group exhibited dramatically decreased signal intensity, demonstrating superior antitumor efficacy. Moreover, the DPPCP patch enabled 100% survival of nude mice over 90 days. In this work, the patch-mediated combined photothermal-chemotherapy strategy holds promise as an alternative to clinical surgical resection and postoperative chemotherapy, addressing the treatment needs of diverse cancer patients.
14 January 2026 in European Journal of Medical Research
Cervical cancer treatment faces challenges in identifying specific targets within heterogeneous tumors. Current antitumor immunotherapy for cervical cancer
New effective early diagnosis strategies and therapeutic targets are desperately needed for high-grade serous ovarian cancer (HGSOC). Previous functional interpretation of HGSOC genome-wide association studies (GWAS) have largely overlooked the role of long non-coding RNAs (lncRNAs). Our study aims to identify novel causal genes, particularly lncRNAs, that contribute to HGSOC susceptibility and to explore whether their may provide preliminary insights relevant to early detection or therapeutic development. We mapped genotype effects on the expression of both protein-coding genes (PCGs) and lncRNAs in 348 HGSOC tumor samples. By performing Bayesian colocalization analysis, we prioritized causal genes in HGSOC tumors and whole blood, respectively. Next, we generated a single-nucleus full-length transcriptome map of HGSOC tumor using snRandom-seq. Furthermore, we conducted in vitro assays to validate the functional role of lncRNA CRHR1-IT1 in HGSOC. Our findings reveal that genetic variants significantly drive expression changes in both PCGs and lncRNAs. Notably, lncRNAs contribute a greater proportion of HGSOC heritability than PCGs. Using Bayesian colocalization analysis, we prioritized 22 high-fidelity causal genes in HGSOC tumors and whole blood, including ARL17A and CRHR1-IT1. Through snRandom-seq, we characterized the single-cell expression patterns of candidate susceptibility PCGs and lncRNAs in HGSOC tumors. Furthermore, we showed that elevated CRHR1-IT1 expression promotes apoptosis and inhibits the growth of HGSOC cells in vitro. Our study highlights the significant regulatory role of genetic variants on both protein-coding genes and lncRNAs in HGSOC. While these findings enhance our understanding of HGSOC susceptibility and may inform future efforts toward biomarker discovery or immune-related therapeutic exploration.